IRAK4 inhibiting agents
Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.
1. A compound represented by the formula
or a pharmaceutically acceptable salt thereof, wherein:
one of W and X is N, and the other of W and X is C;
R 1 is C 1-6 alkyl optionally substituted with N(R 10 ) 2 ;
R 10 is H or C 1-4 alkyl;
R 2 is H, F or —OR 2a ;
R 2a is H or C 1-4 alkyl;
R 3 is C(O)N(R 3a ) 2 or C 1-4 alkyl, wherein said C 1-4 alkyl is optionally substituted with one to three halo or —OR 3a ; and
R 3a in each occurrence is independently selected from H and C 1-4 alkyl.
2. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
3. A method for treating rheumatoid arthritis or ischemic kidney injury in a subject, comprising administering to the patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, thereby treating rheumatoid arthritis or ischemic kidney injury.
4. The method of claim 3 , wherein the method is for treating rheumatoid arthritis.
5. The compound of claim 1 , wherein the compound is represented by the following structural formula:
or a pharmaceutically acceptable salt thereof.
6. The compound of claim 1 , wherein the compound is represented by the following structural formula:
or a pharmaceutically acceptable salt thereof.